Studies from University Hospital, Department of Oncology in the area of esophageal cancer therapy described
2007 NOV 19 -- Investigators publish new data in the report 'Activation of growth factor receptors in esophageal cancer--implications for therapy.' According to a study from Uppsala, Sweden, "Esophageal cancer is a highly aggressive disease and is the seventh most common cause of cancer-related death in the western world. Worldwide, it ranks as the sixth most frequent cause of cancer death." "Despite advances in surgical techniques and treatment, the prognosis of esophageal cancer remains poor, with very few long-term survivors. The need for novel strategies to detect esophageal cancer earlier and to improve current therapy is urgent. It is well established that growth factors and growth factor receptor-mediated signaling pathways are important components of the transformation process in many forms of cancer, including esophageal cancer. With the recent advances in drug development, there are emerging possibilities to use growth factor signal transduction pathways in targeted therapy," wrote S. Ekman and colleagues, University Hospital, Department of Oncology. The researchers concluded: "This review provides a summary of the role of growth factors and their receptors in esophageal cancer and discusses their potential roles as biomarkers and as targets in therapy." Ekman and colleagues published their study in Oncologist (Activation of growth factor receptors in esophageal cancer--implications for therapy. Oncologist, 2007;12(10):1165-77). For more information, contact S. Ekman, University Hospital, Dept. of Oncology, Uppsala, Sweden. Publisher contact information for the journal Oncologist is: Alphamed Press, One Prestige Place, Ste. 290, Miamisburg, OH 45342-3758, USA. Keywords: Sweden, Uppsala, Esophageal Cancer Therapy, Drug Development, Esophageal Cancer, Esophageal Carcinoma, Oncology, Pharmaceuticals, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
